1159812-31-3

Basic information

• Product Name: 6-Tributylstannyl[1,2,4]triazolo[1,5-a]pyridine
• Synonyms: 6-Tributylstannyl[1,2,4]triazolo[1,5-a]pyridine;5-a]pyridine;6-Tributylstannyl[1;7-broMo-2-Methyl-[1;7-BroMo-2-Methyl-[1,2,4]triazolo[1,5-a]pyridine
• CAS NO: 1159812-31-3
• Molecular Weight: 212.049
• Mol File: 1159812-31-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 6-Tributylstannyl[1,2,4]triazolo[1,5-a]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Tributylstannyl[1,2,4]triazolo[1,5-a]pyridine(1159812-31-3)
• EPA Substance Registry System: 6-Tributylstannyl[1,2,4]triazolo[1,5-a]pyridine(1159812-31-3)

Safety Data

• Hazardous Substances Data: 1159812-31-3(Hazardous Substances Data)

Usage

General Description

6-Tributylstannyl[1,2,4]triazolo[1,5-a]pyridine is an organotin compound with the chemical formula C20H31N4Sn. It is a derivative of the triazolopyridine family and contains a tributylstannyl group. This chemical is often used as a building block in organic synthesis, particularly in the preparation of functionalized heterocyclic compounds. It has been found to exhibit potential biological activity, making it a promising candidate for medicinal chemistry research. Additionally, its tributylstannyl group makes it a useful reagent in cross-coupling reactions for the formation of C-C and C-N bonds. However, it is important to handle this compound with caution, as organotin compounds can have toxic effects on humans and the environment.

Upstream product

• 108-24-7 acetic anhydride 
• 1202704-61-7 1,2-diamino-4-bromopyridin-1-ium-2,4,6-trimethylbenzenesulfonate 

Downstream Products

• 1236325-11-3 (S)-6-(2-hydroxy-2-methyl-propyl)-3-{(S)-1-[4-(2-methyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-phenyl]-ethyl}-6-phenyl-[1,3]oxazinan-2-one 
• 1202701-57-2 C₁₉H₁₆FN₇O₂ 

Relevant articles and documents

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

OXAZOLIDINONE DERIVATIVE HAVING FUSED RING

The present invention provides a novel antimicrobial drug comprising an oxazolidinone derivative of the formula (I): or a pharmaceutically acceptable salt or solvate thereof; wherein ring A is ring B is a benzene ring optionally substituted with lower alkyl; ring C is an optionally substituted six-membered heterocycle containing at least one nitrogen atom and one to three double bond(s) in the ling wherein the atom at the point of attachment to ring B is a carbon atom; ring D is an optionally substituted five-membered ring containing one or two double bond(s) in the ring; A1 and A2 are independently nitrogen or carbon; m is 0 or 1; R represents H, —NHC(═O)RA, —NHC(═S)RA, —NH-het1, —O-het1, —S-het1, —S(═O)-het1, —S(═O)2-het1, het2, —CONHRA, —OH, lower alkyl, lower alkoxy or lower alkenyl; and het1 and het2 are independently a heterocyclic group; with the proviso that the fused ring C-D is not